The program will bring together experts from across the FDA for a team-based review, rather than having an application move ...

Nearly $30 million in tax incentive awards are expected to add 1,519 new life sciences jobs in Massachusetts, with about 52% ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

HHS Secretary Robert F. Kennedy Jr.’s actions in recent months have raised concerns that he is taking a heavy-handed and ...

At a satellite kickoff event to the annual BIO meeting, investment bankers and VCs gave reasons for optimism amid a ‘volatile ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

District Judge William Young, a nominee of Republican President Ronald Reagan, blasted the Trump administration’s NIH cuts as discriminatory and “bearing down on people of color because of their color ...

NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from ...